#atrial-fibrillation #cardiac-arrhythmias #anticoagulation #supraventricular-tachycardia #catheter-ablation

Atrial Flutter (AFL)

Details

Atrial flutter is one of the most common atrial tachyarrhythmias, typically arising from a macro-reentrant circuit in the right atrium dependent on the cavo-tricuspid isthmus (CTI). It is closely associated with atrial fibrillation, sharing similar risk factors, and the majority of AFL patients eventually develop AF.

Key Facts

Incidence: 88 per 100 000 person-years overall; rises to 317 per 100 000 person-years in people >50 years (sources/AF-ESC-2024, rating: very high)
More than 50% of all patients with AFL will develop AF during follow-up (sources/AF-ESC-2024)
Thromboembolic risk is elevated in AFL; observational data show similar or slightly lower stroke risk vs. AF, possibly due to confounders (comorbidity, anticoagulation patterns) (sources/AF-ESC-2024)
OAC recommended in AFL patients at elevated thromboembolic risk (CHA2DS2-VA), analogous to AF management (Class I/B) (sources/AF-ESC-2024)
Rate control can be difficult in AFL; rhythm control with CTI ablation is often first-line (sources/AF-ESC-2024)
CTI ablation is superior to antiarrhythmic drugs for typical AFL (small RCTs); bidirectional block in the CTI is the procedural endpoint (sources/AF-ESC-2024)
AFL recurrence is uncommon after confirmed bidirectional CTI block; however, 50–70% of patients develop AF during long-term follow-up after AFL ablation (sources/AF-ESC-2024)
Long-term dynamic reassessment (AF-CARE approach) is essential for all AFL patients given the high rate of subsequent AF development (sources/AF-ESC-2024)
Management of comorbidities and risk factors in AFL mirrors the approach for AF (sources/AF-ESC-2024)

AHA 2023 Anticoagulation Recommendations for AFL

OAC recommended per same risk profile as AF (Class I/B-NR) (sources/AF-AHA-2023, rating: very high)
OAC continued ≥4 weeks after cardioversion or ablation (Class I/C-LD) (sources/AF-AHA-2023)
Patients with prior AF before CTI ablation: ongoing OAC as for AF (Class I/A) (sources/AF-AHA-2023)
Patients without prior AF after successful CTI ablation at high stroke risk: close AF monitoring recommended (Class I/B-NR); if at high risk for AF development (LA enlargement, inducible AF, COPD, HF), long-term OAC may be reasonable (Class IIb/B-NR) (sources/AF-AHA-2023)
AF incidence after CTI ablation: 16–82% in long-term follow-up; in one series, 82% developed AF over 39 months follow-up (sources/AF-AHA-2023)
Stroke rate in AFL patients without anticoagulation: 4.1% vs. 1.2% in matched controls (sources/AF-AHA-2023)
AFL is 2.5× more common in men; higher incidence in HF and COPD (sources/AF-AHA-2023)

ACC/AHA/HRS 2015 SVT Guideline Recommendations for Atrial Flutter

Classification

CTI-dependent (typical): Counterclockwise circuit around tricuspid annulus; sawtooth waves in II/III/aVF (negative), positive in V1; atrial rate 250–350 bpm
CTI-dependent (reverse typical): Clockwise circuit; positive inferior leads, wide negative V1
Non-CTI-dependent (atypical): Macroreentrant circuits around mitral annulus, scar, or post-AF ablation lesions; ECG morphology unreliable to distinguish from CTI-dependent post-AF ablation; requires EP study with intracardiac mapping sources/svt-aha-2015 (rating: very high)

Acute Treatment (ACC/AHA/HRS 2015)

Class I/A: Oral dofetilide or IV ibutilide for pharmacological cardioversion (~60% conversion with ibutilide); risk of TdP (worse with reduced LVEF); IV Mg pretreatment improves safety and efficacy; 4h continuous ECG monitoring post-ibutilide
Class I/B-R: IV or oral beta blockers, diltiazem, or verapamil for rate control (hemodynamically stable); IV diltiazem preferred IV CCB due to safety profile; esmolol preferred IV BB
Class I/B-NR: Elective synchronized cardioversion if rhythm control strategy and hemodynamically stable; lower energy requirements than AF
Class I/B-NR: Synchronized cardioversion for hemodynamically unstable flutter
Class I/C-LD: Rapid atrial pacing for acute conversion if pacing leads in place (>50% effective; converts flutter to AF which is often more easily rate-controlled)
Class I/B-NR: Acute antithrombotic therapy per AF anticoagulation guidelines; stroke risk in flutter similar to AF (3% annually in sustained flutter; 0–7% short-term post-cardioversion)
Class IIa/B-R: IV amiodarone for rate control in flutter + systolic HF when beta-blockers contraindicated sources/svt-aha-2015

Ongoing Management (ACC/AHA/HRS 2015)

Class I/B-R: CTI ablation — preferred for symptomatic or pharmacologically refractory flutter; >97% acute success; bidirectional block as procedural endpoint; superior to long-term antiarrhythmic drugs
Class I/B-NR: Ongoing anticoagulation per AF guidelines
Class I/C-LD: Beta blockers, diltiazem, or verapamil for rate control if CTI ablation not pursued (rate control more difficult than in AF)
Class I/C-LD: Ablation for recurrent symptomatic non-CTI flutter after failure of ≥1 antiarrhythmic drug
Class IIa/B-R): Amiodarone, dofetilide, or sotalol to maintain sinus rhythm in symptomatic recurrent flutter (if ablation not pursued)
Class IIa/B-NR: CTI ablation if flutter induced by flecainide/propafenone/amiodarone used for AF treatment
Class IIa/C-LD: CTI ablation concurrent with AF ablation if history of documented clinical or induced CTI flutter
Class IIa/C-LD: Ablation as primary therapy for recurrent symptomatic non-CTI flutter before antiarrhythmic drug trials (carefully weighing risks)
Class IIb/B-R: Flecainide or propafenone for sinus rhythm maintenance without structural/ischemic heart disease (MUST combine with AV nodal blocker to prevent 1:1 flutter conduction)
Class IIb/C-LD: Ablation for asymptomatic recurrent flutter to prevent tachycardia-mediated cardiomyopathy
Note: Rate control in flutter paradoxically more difficult than in AF (slower atrial rate = less concealed AV nodal conduction); higher doses of AV nodal agents or combination therapy often required sources/svt-aha-2015

AF Development After CTI Ablation

22–50% of patients develop AF within 14–30 months after CTI ablation; one series: 82% within 5 years
Risk factors: prior AF, LV dysfunction, large LA, structural heart disease, inducible AF
Post-CTI ablation monitoring and long-term anticoagulation in high-risk patients is warranted sources/svt-aha-2015

Non-CTI Flutter Considerations

Occurs after cardiac surgery (atriotomy incisions, cannulation sites) or AF ablation (~5% post-ablation)
Isolated pulmonary vein isolation = less risk than linear lesion-based AF ablation
Post-AF ablation flutter: defer ablation to 3-month waiting period unless pharmacotherapy/cardioversion fail; most periprocedural flutters resolve spontaneously
Complex anatomy, multiple circuits, prior ablation lesions → lower success rates (73–100%), higher recurrence (7–53%) sources/svt-aha-2015

ESC 2019 Guidelines for Atrial Flutter / Macro-Re-entrant AT

Acute (ESC 2019)

Haemodynamically unstable: DC cardioversion I/B
Ibutilide IV or dofetilide IV/oral (in-hospital): I/B (upgraded from IIa in 2003)
Low-energy (<100 J biphasic) electrical cardioversion: I/B
High-rate atrial pacing (with implanted device): I/B
IV beta-blockers or CCBs for rate control: IIa/B
Invasive/non-invasive high-rate atrial pacing: IIb/B
IV amiodarone: IIb/C (downgraded from I in 2003)
Flecainide/propafenone: III/B (contraindicated) — risk of 1:1 flutter conduction by slowing atrial rate
Adenosine: may increase AV block to reveal flutter pattern but can cause rebound 1:1 conduction or precipitate AF — use only if needed for diagnosis with resuscitation equipment available sources/svt-esc-2019 (rating: very high)

Chronic (ESC 2019)

CTI ablation for symptomatic recurrent CTI-dependent flutter: I/A (strongest recommendation)
CTI ablation considered after first symptomatic episode: IIa/B
Non-CTI-dependent flutter ablation in experienced centres: I/B
Ablation for persistent flutter or LV dysfunction from TCM: I/B
Beta-blockers or CCBs if ablation not feasible: IIa/C
Amiodarone to maintain sinus rhythm: IIb/C
AV nodal ablation + pacing (biventricular or His-bundle) if all else fails: IIa/C sources/svt-esc-2019

Anticoagulation (ESC 2019)

Concomitant AF: anticoagulation as for AF — I/B
Flutter without AF: anticoagulation IIa/C — threshold not established; CHA₂DS₂-VASc not validated for isolated flutter; thromboembolic risk of flutter lower than AF but still significant; thrombi and LA appendage stunning lower than in AF but present
Pre-cardioversion anticoagulation: treat as for AF when flutter lasts >48 hours sources/svt-esc-2019

ESC vs AHA Comparison for Atrial Flutter

Topic	AHA 2015	ESC 2019
CTI ablation first symptomatic episode	IIa	IIa/B (consistent)
CTI ablation recurrent	I/B-R	I/A (stronger evidence grading)
Ibutilide for cardioversion	I/A	I/B
Atrial pacing for conversion	I	IIb (downgraded)
Flecainide/propafenone chronic	IIb	Not recommended (not mentioned)
Anticoagulation isolated flutter	Per AF guidelines	IIa/C (threshold not established)

Contradictions / Open Questions

Anticoagulation threshold for isolated atrial flutter without AF: AHA 2015 recommends treating as AF; ESC 2019 acknowledges the threshold is "not established" and downgrades to IIa/C; CHA₂DS₂-VASc not validated for isolated flutter sources/svt-aha-2015 sources/svt-esc-2019
Some studies suggest lower stroke risk in AFL vs. AF; others show similar risk — the true thromboembolic risk differential remains uncertain (sources/AF-ESC-2024, sources/AF-AHA-2023)
Non-CTI flutter: no RCTs comparing ablation vs antiarrhythmic drugs — all guidance based on observational data sources/svt-aha-2015 sources/svt-esc-2019
Optimal anticoagulation duration post-CTI ablation in patients without prior AF history: remains debated; ESC 2019 recommends close rhythm monitoring; long-term OAC in high AF risk patients